07:00 , Oct 6, 2014 |  BioCentury  |  Finance

3Q14 Stock Wrap-Up: Going big again

For the second quarter in a row, only the large caps finished in the black in 3Q14. In the over $5 billion segment, which was up 9%, gainers outnumbered decliners 22-9, while the decliners led...
07:00 , Sep 8, 2014 |  BC Week In Review  |  Company News

Novo Nordisk pharmaceuticals news

Novo Nordisk is discontinuing R&D within inflammatory disorders and will expand R&D in diabetes and obesity. The decision follows a strategic review after Novo discontinued development of its lead compound in the inflammatory disorders space,...
01:20 , Sep 3, 2014 |  BC Extra  |  Company News

Novo Nordisk discontinues inflammation R&D

Novo Nordisk A/S (CSE:NVO; NYSE:NVO) is discontinuing all inflammatory disease R&D. Novo ended development of its lead compound in the space, NN8226, which is a recombinant human mAb neutralizing IL-20 in Phase II trials to...
08:00 , Feb 7, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Bladder cancer IL-20; IL-20 receptor-a (IL20R1; IL20RA); cyclin-dependent kinase inhibitor 1A (p21, Cip1)...
08:00 , Feb 2, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer IL-20 Studies in mice and in human samples suggest inhibiting IL-20 could help treat breast...
08:00 , Feb 2, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Bladder cancer Keratin 14 (KRT14) Patient sample studies suggest KRT14 could help predict bladder cancer prognosis. In...
07:00 , Sep 1, 2011 |  BC Innovations  |  Cover Story

IL-20's osteoporosis connection

A group of Taiwanese researchers has shown that an antibody against IL-20 helped treat osteoporosis in mice.1 The findings have grabbed the attention of Novo Nordisk A/S, which has an anti-IL-20 mAb in Phase II...
07:00 , Aug 25, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Musculoskeletal disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Musculoskeletal disease Osteoporosis IL-20 In vitro and mouse studies suggest IL-20 inhibitors could help treat osteoporosis. In osteoporosis...
08:00 , Feb 5, 2007 |  BioCentury  |  Strategy

Sticking to core values

Novo Nordisk A/S is dropping small molecules in order to focus on turning its mature biologics franchise into an engine for growth and diversification. By returning to its recombinant protein roots, the company hopes to...